Free Trial

Avalon GloboCare (ALBT) Competitors

Avalon GloboCare logo
$2.27 -0.70 (-23.57%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 -0.10 (-4.19%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALBT vs. CTXR, ATHA, CASI, PRPH, ALLR, MTEX, EQ, ERNA, PMN, and LPTX

Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), CASI Pharmaceuticals (CASI), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Mannatech (MTEX), Equillium (EQ), Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry.

Avalon GloboCare vs. Its Competitors

Avalon GloboCare (NASDAQ:ALBT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

In the previous week, Avalon GloboCare had 3 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Avalon GloboCare and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.89 beat Avalon GloboCare's score of 1.39 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Avalon GloboCare Positive
Citius Pharmaceuticals Very Positive

Citius Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 3,505.44%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Avalon GloboCare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon GloboCare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Citius Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Avalon GloboCare has higher revenue and earnings than Citius Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalon GloboCare$1.33M3.23-$7.90M-$19.96-0.11
Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Citius Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalon GloboCare-647.29% N/A -50.13%
Citius Pharmaceuticals N/A -58.63%-37.67%

Avalon GloboCare has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Summary

Citius Pharmaceuticals beats Avalon GloboCare on 8 of the 13 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALBT vs. The Competition

MetricAvalon GloboCareMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.63M$3.02B$5.70B$9.56B
Dividend YieldN/A2.40%4.71%4.06%
P/E Ratio-0.1121.0028.1919.94
Price / Sales3.23331.94459.6596.38
Price / CashN/A42.5736.3258.72
Price / Book-0.208.138.295.77
Net Income-$7.90M-$55.06M$3.25B$259.21M
7 Day Performance-6.20%0.88%0.21%-0.80%
1 Month Performance-18.35%15.04%8.71%9.81%
1 Year Performance-60.49%2.54%32.76%14.37%

Avalon GloboCare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALBT
Avalon GloboCare
1.3859 of 5 stars
$2.27
-23.6%
N/A-51.1%$5.63M$1.33M-0.115News Coverage
Positive News
Gap Down
CTXR
Citius Pharmaceuticals
3.0698 of 5 stars
$1.44
-5.9%
$53.00
+3,580.6%
-93.6%$16.27MN/A0.0020Positive News
ATHA
Athira Pharma
3.7346 of 5 stars
$0.43
+5.6%
$11.25
+2,510.2%
-87.5%$15.93MN/A-0.2140Positive News
Upcoming Earnings
CASI
CASI Pharmaceuticals
4.2205 of 5 stars
$1.22
-3.2%
$4.00
+227.9%
-75.5%$15.50M$28.54M-0.48180Positive News
Gap Up
PRPH
ProPhase Labs
0.4185 of 5 stars
$0.40
+10.3%
N/A-86.2%$15.18M$6.77M0.00130News Coverage
ALLR
Allarity Therapeutics
2.1417 of 5 stars
$0.97
-2.3%
N/A-83.2%$15.03MN/A0.0010Upcoming Earnings
Analyst Forecast
MTEX
Mannatech
1.0269 of 5 stars
$8.08
+2.8%
N/A+8.9%$14.94M$115.04M-80.80250
EQ
Equillium
2.8791 of 5 stars
$0.41
-0.2%
$3.00
+624.5%
-45.5%$14.83M$41.10M-1.0640Positive News
Gap Down
ERNA
Ernexa Therapeutics
1.0767 of 5 stars
$1.96
-1.0%
N/A-93.0%$14.58M$580K-0.2410Positive News
PMN
Promis Neurosciences
2.9749 of 5 stars
$1.12
+154.5%
$4.33
+286.9%
-43.7%$14.39MN/A-22.405News Coverage
Positive News
High Trading Volume
LPTX
Leap Therapeutics
1.9336 of 5 stars
$0.34
-1.5%
$3.38
+895.6%
-84.6%$14.26MN/A-0.2040Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:ALBT) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners